Karyopharm Therapeutics (NASDAQ:KPTI) Downgraded by Zacks Investment Research to Hold

Zacks Investment Research cut shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a buy rating to a hold rating in a research note issued to investors on Saturday morning, Zacks.com reports.

According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “

Several other equities research analysts have also recently commented on the company. ValuEngine raised Zillow Group from a hold rating to a buy rating in a research report on Thursday, July 11th. HC Wainwright reaffirmed a buy rating and set a $48.00 price objective (down from $52.00) on shares of CELYAD SA/ADR in a research report on Friday, July 5th. Robert W. Baird reaffirmed an outperform rating and set a $25.00 price objective (up from $15.00) on shares of Karyopharm Therapeutics in a research report on Friday, July 5th. Wedbush set a $11.00 price objective on Sangamo Therapeutics and gave the company a hold rating in a research report on Monday, July 8th. Finally, BidaskClub raised Zumiez from a sell rating to a hold rating in a research report on Saturday, June 22nd. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of $17.41.

NASDAQ KPTI opened at $7.91 on Friday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 6.19 and a current ratio of 6.19. Karyopharm Therapeutics has a 12 month low of $3.92 and a 12 month high of $21.71. The stock has a market capitalization of $511.22 million, a PE ratio of -2.52 and a beta of 2.44. The business has a fifty day moving average of $6.52.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Thursday, May 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.25). Karyopharm Therapeutics had a negative net margin of 1,005.85% and a negative return on equity of 119.66%. The business had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.75 million. As a group, equities research analysts expect that Karyopharm Therapeutics will post -3.79 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of KPTI. Ridgeback Capital Investments L.P. bought a new position in Karyopharm Therapeutics in the fourth quarter valued at about $36,967,000. Candriam Luxembourg S.C.A. lifted its holdings in Karyopharm Therapeutics by 65.1% in the fourth quarter. Candriam Luxembourg S.C.A. now owns 1,792,544 shares of the company’s stock valued at $16,795,000 after acquiring an additional 707,044 shares during the period. FMR LLC lifted its holdings in Karyopharm Therapeutics by 51.5% in the fourth quarter. FMR LLC now owns 1,875,140 shares of the company’s stock valued at $17,570,000 after acquiring an additional 637,357 shares during the period. Frontier Capital Management Co. LLC lifted its holdings in Karyopharm Therapeutics by 311.9% in the first quarter. Frontier Capital Management Co. LLC now owns 683,363 shares of the company’s stock valued at $3,991,000 after acquiring an additional 517,464 shares during the period. Finally, First Midwest Bank Trust Division lifted its holdings in Karyopharm Therapeutics by 259.2% in the first quarter. First Midwest Bank Trust Division now owns 610,850 shares of the company’s stock valued at $3,567,000 after acquiring an additional 440,769 shares during the period. 84.20% of the stock is currently owned by institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.

Recommended Story: Why are gap-down stocks important?

Get a free copy of the Zacks research report on Karyopharm Therapeutics (KPTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit